Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Profits and Lawsuits for Generic Drug Makers
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 08/22/12 -- has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on (NASDAQ: MYL) and (NYSE: WPI). Register with us now to have free access to these research reports. Simply click on the link below.
For companies in the generic drug industry, lawsuits are part of the operating environment and can mean the difference between soaring profits and disappointing losses. Several companies including Watson Pharmaceuticals Inc. are currently involved in litigation and it will be interesting to see how things settle moving forward. report is accessible for free by registering today at
ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.
The industry, which features companies such as Mylan Inc., has been benefitting from a number of high profile patent expirations as of late, and individual company earnings are reflective of this. Get your free reports on and at . There is no commitment to join.
The industry is also well positioned to take advantage of cash-conscious consumers who are currently looking for ways to cut down on expenses. In its most recent quarter, Mylan saw adjusted diluted earnings per share grow by 15% year-over-year, and was also able to increase revenues by 7%. Mylan also recently stated that it is now selling a generic version of Takeda Pharmaceuticals' Actos® Tablets and Actoplus Met® Tablets, used in improving glycemic control in adults that have type 2 diabetes mellitus. report is accessible for free by registering today at
The two stocks research reports are available for free by signing up now on the link below.
Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.
To view our visit this link .
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2012 - 12:05 Uhr
Sprache: Deutsch
News-ID 176691
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 1232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Profits and Lawsuits for Generic Drug Makers"
steht unter der journalistisch-redaktionellen Verantwortung von
Shinesrooms.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
